

Nov 27, 2017

MockV Solutions Announces Collaboration with MedImmune for Predicting Viral Clearance with MVM-MVP Kit

Rockville, MD – Nov 27, 2017 – MockV Solutions, Inc. (MockV or the Company), a biotechnology company developing non-infectious viral clearance prediction products that address the unmet needs of process development scientists as they establish biopharmaceutical manufacturing platforms, announced today that it will be collaborating with MedImmune LLC to evaluate its MVM-MVP Kit. The MVM-MVP Kit contains a non-infectious “Mock Virus Particle” (MVP) that mimics the physicochemical characteristics of Minute Virus of Mice (MVM) and quantification reagents for clearance analysis. The intention of this collaboration is to determine if the non-infectious MVP could be used as an accurate and economic indicator of MVM clearance during small scale bioprocess development studies.

MVM, a small and physiochemically resistant parvovirus, is an international standard for assessing viral clearance during regulatory required validation studies. Currently, assessments are made by propagated and spiking infectious MVM into biopharmaceutical material, processing the material through a scale down version of a manufacturing process step and determining the removal efficiency of the challenged process step. These studies are costly, time consuming and require specialized facilities. MockV’s MVM-MVP Kit is designed to alleviate these challenges and enable process development scientist to efficiently optimize robust manufacturing processes that meet viral clearance regulatory requirements.

“We enthusiastically support MockV in its efforts to establish a series of tools that will enable us to economically and easily analyze viral clearance during process development and characterization,” stated Dr. Matthew Dickson (PhD), Associate Director of R&D at MedImmune. “We are working with MockV to progress this technology and share their vision of incorporating viral clearance as a measurable output during typical process development and optimization activities.”

“We look forward to working with MedImmune as we advance our lead product toward commercialization,” stated David Cetlin M.S. Chief Executive Officer of MockV. “Both MockV and MedImmune believe that the MVM-MVP Kit has the potential to address the current challenges and shortcomings of viral clearance as it relates to process development and optimization. We are excited to move forward with this collaboration and advance the capabilities of our industry.”

About MedImmune

MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development

and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular & Metabolic Diseases, and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca's three global R&D centres, with additional sites in Cambridge, UK and Mountain View, CA. For more information, please visit www.medimmune.com

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

About MockV Solutions, Inc.

MockV Solutions, Inc. (MVS) is a biotechnology company commercializing non-infectious viral-surrogate tools to a variety of industries that currently rely on expensive and logistically challenging live virus analysis. MockV is developing a novel series of analytical assay kits which will enable biopharmaceutical process development scientists to study the efficacy of manufacturing techniques intended to remove or inactivate virus, a contaminant of great concern during the manufacturing of biopharmaceuticals. These products are only approved for clinical or commercial use after their manufacturing processes demonstrate sufficient viral clearance. Currently, this is accomplished through the use of live mammalian model viruses (ex. MVM and XMuLV) in expensive and logistically challenging "spiking studies". The lack of economical and accurate means of analyzing viral clearance during small scale process development increases the risk of failing viral clearance regulatory requirements - jeopardizing the timely approval of potentially life-altering therapies. MockV's lead product candidate, the MVM-MVP Kit contains a non-infectious "Mock Virus Particle" (MVP) that mimics the physicochemical characteristics of live infectious MVM, as well as reagents and components to quantify MVP in solution. Prototypes are available for sale.

For further information regarding MockV Solutions, Inc., please visit the Company's website at www.mockvsolutions.com.